2012-000299-40
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
Novartis Pharma Services AG·EU Clinical Trials Register
Study focus
- Disease/Condition
- Healthy volunteers
Sponsor & location
- Primary sponsor
- Novartis Pharma Services AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Primary pharmacokinetic parameters: AUC(0-t), AUC(0-inf) and Cmax
ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2012-000299-40
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2012-000299-40 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma Services AG and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.